BACKGROUND: Men diagnosed with localised prostate cancer (PC) have to make a well-informed treatment choice between (robot-assisted) radical prostatectomy (RARP), external beam radiotherapy (EBRT) and, in selected cases, brachytherapy and active surveillance.
We developed and validated a questionnaire to determine the cognitive reasons why patients choose their treatment.
MATERIALS AND METHODS: The Prostate Cancer Decision-Making Questionnaire (PC-DMQ) was designed in-house and validated through the Delphi method by seven external experts. Finally, we tested this questionnaire in a cohort of 24 men, recently diagnosed with localised PC, before undergoing RARP (n = 16), EBRT (n = 6), brachytherapy (n = 1) or active surveillance (n = 1).
RESULTS: The experts reached consensus after three discussion rounds. In the patient cohort, 75% of men undergoing RARP chose this treatment because 'it provides the best chance of cure'. Reasons to choose EBRT were not as explicit: 33.3% chose this treatment because 'it provides the best chance of cure' and 33.3% because 'the maintenance of potency is important to them'.
CONCLUSIONS: The PC-DMQ is a comprehensive and standardised tool that allows further research into cognitive factors that influence treatment decision-making in patients with localised PC.
Devos J, Van Praet C, Decaestecker K, Claeys T, Fonteyne V, Decalf V, De Meerleer G, Ost P, Lumen N. Are you the author?
Reference: Acta Clin Belg. 2015 Mar 27:2295333715Y0000000015.